AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 41 min read$SYRE

Turtle Cameron sold $1.1M of SYRE

Turtle Cameron (Chief Executive Officer) sold 15,000 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $70.43 ($69.40–$71.38, $1.06M total) across 3 trades on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Turtle Cameron
Published Jun 4, 2026, 1:31 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 3:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SYRE
Bearish
high confidence
Mentioned
$SYRE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SYREBearishLow
01

Why it matters

The insider sale may trigger short‑term price weakness, but the 10b5‑1 plan suggests pre‑planned execution.

02

Market read

Primary insider sale provides fresh data for traders evaluating SYRE's near‑term risk.

03

What to watch

Potential upcoming clinical data or partnership announcements could offset sell pressure.

Relevance 5/10Novelty 7/10Timing: pre‑market today

Background

Form 4 filing by Spyre Therapeutics CEO discloses a $1.05M share sale.

Company-level read

Ticker impact

$SYREBearishHigh confidence
Context

CEO Turtle Cameron sold 15,000 shares for $1.06M via a 10b5-1 plan, reducing his stake to 597,540 shares.

Expected impact

likely downward pressure as market prices in the insider sell

Evidence & confidence

The sale is sizable for a micro‑cap and was disclosed through a primary Form 4 filing.

Market effects

Sector

Minimal; biotech sector may see slight sentiment drag from insider sell.

Regional

U.S. market only; no broader regional effect.

Global

Low; limited to SYRE investors.

Counterpoint

What could challenge this read

The sale could be routine under a 10b5‑1 plan and not indicate fundamental weakness.

Key entities

  • Company
    Spyre Therapeutics, Inc.

    Biotech firm listed as SYRE.

  • Executive
    Turtle Cameron

    CEO and Director of Spyre Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SYRE insider trading history →

Related articles

OCT 18
$SYREHighAI 9/10

Spyre presents clinical data on IBD antibody therapies

Spyre Therapeutics (NASDAQ:SYRE) presented clinical data on three IBD antibody therapies (SPY001, SPY002, SPY003) at UEGW 2026, showing proof-of-concept. The SKYLINE study tests these therapies as monotherapies and combinations. Silvio Danese, SKYLINE trial chair, expressed excitement for future combination results.

investing.com2 min
OCT 18
$SYREMed

Mouse studies found combinations of experimental bowel treatments worked better

Spyre Therapeutics (NASDAQ: SYRE) presented preclinical data at UEGW 2026, showing additive efficacy of its IBD antibody combinations (SPY001, SPY002, SPY003) in mouse studies. The company is testing these as monotherapies and combinations in the SKYLINE trial, with clinical proof-of-concept demonstrated across all three antibodies. Spyre aims to raise the therapeutic ceiling for IBD patients with these advanced combination therapies.

stocktitan.net2 min
OCT 16
$SYREMedAI 8/10

Jefferies says this stock remains a top pick among biotech midcaps

Jefferies named Spyre Therapeutics its top pick in small- to mid-cap biotech, citing its pipeline of combination therapies for inflammatory bowel disease. The company's three treatments are expected to report Phase 2 data in 2027. Jefferies highlighted encouraging efficacy signals and favorable safety profiles, with real-world data showing high remission rates.

investing.com2 min
OCT 9
Med

Why is Spyre Therapeutics stock rallying today?

Spyre Therapeutics' stock rose 4.4% in morning trading, recovering from a selldown after a $350M public offering priced at $85 per share. Jefferies highlighted Syros Pharmaceuticals as a top biotech pick for 2027, citing positive data on combination therapies for inflammatory bowel diseases. The broader market also gained, with the S&P 500, Dow Jones, and Nasdaq posting modest increases.

investing.com2 min